Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AGI-5198 + Crenolanib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AGI-5198 | AG5198|AGI 5198|IDH-C35 | IDH1 Inhibitor 8 | AGI-5198 is a selective inhibitor of mutant forms of IDH1, which decreases production of R-2HG, potentially leading to reduced growth of IDH1-mutant tumor cells (PMID: 23558169, PMID: 26368816, PMID: 31151327). | |
Crenolanib | CP-868596|CP-868,596 | FLT3 Inhibitor 69 PDGFR Inhibitor (Pan) 30 | Crenolanib (CP-868596) is a type III receptor tyrosine kinase inhibitor of PDGFR-alpha/beta and FLT3, which results in inhibition of downstream signaling and prevents growth in tumor cells (PMID: 22745105, PMID: 24227820, PMID: 29137311, PMID: 31309543). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 D835Y IDH1 R132H | hematologic cancer | sensitive | AGI-5198 + Crenolanib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Crenolanib (CP-868596) and AGI-5198 synergistically decreased proliferation of transformed cells expressing FLT3 D835Y and IDH1 R132H in culture (PMID: 30651561). | 30651561 |
FLT3 exon 14 ins IDH1 R132H | hematologic cancer | sensitive | AGI-5198 + Crenolanib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing FLT3-ITD and IDH1 R132H demonstrated increased sensitivity to treatment with the combination of Crenolanib (CP-868596) and AGI-5198 compared to treatment with Crenolanib (CP-868596) alone in culture (PMID: 30651561). | 30651561 |
FLT3 D835Y IDH1 wild-type | hematologic cancer | sensitive | AGI-5198 + Crenolanib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Crenolanib (CP-868596) and AGI-5198 synergistically decreased proliferation of transformed cells expressing FLT3 D835Y and IDH1 wild-type in culture (PMID: 30651561). | 30651561 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|